Bleakley Financial Group LLC Acquires Shares of 11,159 Celcuity Inc. (NASDAQ:CELC)

Bleakley Financial Group LLC bought a new stake in shares of Celcuity Inc. (NASDAQ:CELC) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 11,159 shares of the company’s stock, valued at approximately $146,000.

A number of other hedge funds have also recently made changes to their positions in CELC. BNP Paribas Financial Markets grew its stake in Celcuity by 2,083.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company’s stock worth $673,000 after acquiring an additional 43,044 shares in the last quarter. Geode Capital Management LLC lifted its stake in Celcuity by 27.6% in the third quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock worth $9,401,000 after acquiring an additional 136,518 shares during the period. State Street Corp increased its position in Celcuity by 152.2% during the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company’s stock valued at $16,512,000 after purchasing an additional 668,318 shares during the period. Braidwell LP increased its holdings in Celcuity by 71.2% during the third quarter. Braidwell LP now owns 884,306 shares of the company’s stock valued at $13,185,000 after buying an additional 367,663 shares during the period. Finally, Barclays PLC lifted its holdings in Celcuity by 567.6% during the third quarter. Barclays PLC now owns 53,605 shares of the company’s stock worth $800,000 after buying an additional 45,576 shares during the period. 63.33% of the stock is currently owned by institutional investors.

Celcuity Stock Performance

Shares of CELC stock opened at $12.41 on Thursday. The business has a 50-day simple moving average of $12.27 and a 200-day simple moving average of $14.24. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a market cap of $460.78 million, a PE ratio of -4.75 and a beta of 0.73. Celcuity Inc. has a 52-week low of $10.35 and a 52-week high of $22.19.

Wall Street Analysts Forecast Growth

CELC has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research note on Friday, November 15th. Needham & Company LLC upped their price objective on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $30.17.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.